NCT00654277View on ClinicalTrials.gov

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

September 30, 2002

Study Completion Date

September 30, 2002

Conditions
Healthy
Interventions
DRUG

Ondansetron

ODT, 8 mg, single-dose

DRUG

Zofran

ODT, 8 mg, fasting conditions

Sponsors

Collaborators (1)

Algorithme Pharma Inc
All Listed Sponsors
collaborator

Algorithme Pharma Inc

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00654277 - Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter